Labroots

Scaling RNAi therapeutics for honeybee health with the Hydrocycler²

Honeybees are vital to global food security, yet colony collapse threatens ecosystems and agriculture worldwide.   Discover ...
The Pharma Letter

Arrowhead’s RNAi trims fat in early PhI/IIa obesity data

Arrowhead Pharmaceuticals today announced interim results from two Phase I/IIa clinical trials of ARO-INHBE and ARO-ALK7, the ...

Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference

Arrowhead Pharmaceuticals (NASDAQ:ARWR) used its presentation at the JPMorgan Healthcare Conference to highlight a newly launched RNA interference (RNAi) therapy, a broad clinical-stage pipeline, and ...
Clinical Trials Arena on MSN

Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial

Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled reductions in visceral fat, total fat ...

Arrowhead Pharmaceuticals Shares Early RNAi Obesity Data, Highlights Visceral Fat Drops and Combo Potential

Arrowhead Pharmaceuticals (NASDAQ:ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity ...
Medical Dialogues

RNAi Therapy Zodasiran Cuts LDL Cholesterol by Up to 40 Percent in Homozygous FH: GATEWAY Trial

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...